Tus Pharmaceutical Group Co Ltd (000590) — Cash Flow-to-Debt Ratio
Tus Pharmaceutical Group Co Ltd (000590) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥2.24 Million could theoretically repay 0% of its total liabilities (CN¥359.74 Million) in one year. See 000590 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tus Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Tus Pharmaceutical Group Co Ltd across 28 annual periods. Also explore 000590 net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tus Pharmaceutical Group Co Ltd (1998–2025)
Year-by-year debt coverage analysis for Tus Pharmaceutical Group Co Ltd. For market capitalisation and broader financial context, see Tus Pharmaceutical Group Co Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | CN¥28.96 Million | CN¥339.98 Million | ▲ +101.9% |
| 2024 | 0.04x | CN¥17.39 Million | CN¥412.18 Million | ▲ +162.8% |
| 2023 | -0.07x | CN¥-28.39 Million | CN¥422.92 Million | ▼ -157.2% |
| 2022 | 0.12x | CN¥54.47 Million | CN¥464.26 Million | ▲ +33.0% |
| 2021 | 0.09x | CN¥25.20 Million | CN¥285.50 Million | ▼ -57.6% |
| 2020 | 0.21x | CN¥51.48 Million | CN¥247.27 Million | ▲ +60.1% |
| 2019 | 0.13x | CN¥29.21 Million | CN¥224.58 Million | ▲ +4608.9% |
| 2018 | 0.00x | CN¥654.24K | CN¥236.88 Million | ▲ +100.9% |
| 2017 | -0.31x | CN¥-89.14 Million | CN¥290.40 Million | ▼ -246.2% |
| 2016 | -0.09x | CN¥-32.51 Million | CN¥366.72 Million | ▲ +44.1% |
| 2015 | -0.16x | CN¥-60.56 Million | CN¥381.64 Million | ▼ -25.5% |
| 2014 | -0.13x | CN¥-50.91 Million | CN¥402.71 Million | ▼ -968.0% |
| 2013 | 0.01x | CN¥4.12 Million | CN¥283.05 Million | ▼ -83.4% |
| 2012 | 0.09x | CN¥19.75 Million | CN¥225.44 Million | ▼ -28.6% |
| 2011 | 0.12x | CN¥30.87 Million | CN¥251.62 Million | ▼ -58.2% |
| 2010 | 0.29x | CN¥84.98 Million | CN¥289.85 Million | ▲ +144.8% |
| 2009 | 0.12x | CN¥34.14 Million | CN¥285.11 Million | ▼ -14.7% |
| 2008 | 0.14x | CN¥34.89 Million | CN¥248.53 Million | ▼ -50.2% |
| 2007 | 0.28x | CN¥68.04 Million | CN¥241.37 Million | ▲ +431.1% |
| 2006 | -0.09x | CN¥-23.33 Million | CN¥274.10 Million | ▼ -160.2% |
| 2005 | 0.14x | CN¥55.96 Million | CN¥396.04 Million | ▲ +19.3% |
| 2004 | 0.12x | CN¥48.46 Million | CN¥409.06 Million | ▲ +306.6% |
| 2003 | -0.06x | CN¥-24.43 Million | CN¥426.00 Million | ▼ -127.0% |
| 2002 | 0.21x | CN¥94.30 Million | CN¥443.96 Million | ▲ +273.4% |
| 2001 | -0.12x | CN¥-51.00 Million | CN¥416.40 Million | ▼ -481.2% |
| 2000 | 0.03x | CN¥8.23 Million | CN¥256.24 Million | ▲ +177.3% |
| 1999 | -0.04x | CN¥-10.35 Million | CN¥249.06 Million | ▼ -244.8% |
| 1998 | 0.03x | CN¥3.89 Million | CN¥135.56 Million | — |